脑膜瘤性腺类固醇激素受体的系统评价与个体参与者数据Meta分析
该系统评价与个体参与者数据Meta分析纳入114篇文章、5810例患者6092个肿瘤,评估孕激素受体(PR)、雄激素受体(AR)和雌激素受体(ER)表达。PR+比例为0.76(95%CI 0.72-0.80),AR+为0.50(95%CI 0.33-0.66),ER+在免疫组化法为0.06(95%CI 0.03-0.10)、配体结合法为0.11(95%CI 0.06-0.20)。激素受体状态与WHO分级、年龄、女性、组织学和部位独立相关。
要点
- PR+脑膜瘤比例为0.76(95%CI 0.72-0.80),AR+为0.50(95%CI 0.33-0.66)。
- ER+检出率随检测方法不同:免疫组化法0.06(95%CI 0.03-0.10),配体结合法0.11(95%CI 0.06-0.20)。
- PR+与年龄(OR 1.11,95%CI 1.09-1.13)和WHO I级(OR 8.09,95%CI 3.55-18.44)独立相关。
核心结论
- 激素受体状态与脑膜瘤已知特征(WHO分级、年龄、女性、组织学和解剖部位)存在强关联。
- 识别这些独立关联有助于更好理解脑膜瘤异质性,并为根据激素受体状态进行患者分层后重新审视靶向激素治疗提供基础。
研究设计与样本
- 系统评价与个体参与者数据Meta分析,检索MEDLINE PubMed 1951年1月1日至2020年12月31日发表的文献。
- 最终纳入114篇文章,涉及5810例患者、6092个肿瘤,采用免疫组化或配体结合法检测PR、ER和/或AR。
- 采用随机效应模型对汇总数据(n=4447)和个体参与者数据(n=1363)进行多水平Meta分析,并以混合效应Meta回归分析独立相关变量。
主要发现
- PR+脑膜瘤比例为0.76(95%CI 0.72-0.80),AR+为0.50(95%CI 0.33-0.66)。
- ER+检出率免疫组化法为0.06(95%CI 0.03-0.10),配体结合法为0.11(95%CI 0.06-0.20)。
- PR+和AR+在女性患者中更常见(PR:OR 1.84,95%CI 1.47-2.29;AR:OR 4.16,95%CI 1.62-10.68)。
- PR+脑膜瘤富集于颅底部位(OR 1.89,95%CI 1.03-3.48)和脑膜内皮型组织学(OR 1.86,95%CI 1.23-2.81)。
- Meta回归显示PR+与年龄(OR 1.11,95%CI 1.09-1.13;p<0.0001)和WHO I级肿瘤(OR 8.09,95%CI 3.55-18.44;p<0.0001)独立相关;ER+与脑膜内皮型组织学负相关(OR 0.94,95%CI 0.86-0.98;p=0.044),与凸面部位正相关(OR 1.12,95%CI 1.05-1.18;p=0.0003)。
临床怎么用
- 作者认为,识别激素受体状态与脑膜瘤特征的独立关联可为根据激素受体状态进行患者分层后重新审视靶向激素治疗提供基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The relationship between patient and meningioma characteristics and hormone receptors (HRs) of progesterone, estrogen, and androgen remains poorly defined despite literature suggesting that meningiomas are sensitive to gonadal steroid hormones. Therefore, the authors sought to collect and compare data on this topic by performing a systematic review and meta-analysis of reported studies of HR status in meningiomas. METHODS: A MEDLINE PubMed literature review conducted for articles published between January 1, 1951, and December 31, 2020, resulted in 634 unduplicated articles concerning meningiomas and HRs. There were 114 articles that met the criteria of detailed detection protocols for progesterone receptor (PR), estrogen receptor (ER), and/or androgen receptor (AR) using immunohistochemistry (IHC) or ligand-binding (LB) assays and simultaneous reporting of HR status with at least one variable among age, sex, histology, location, grade, or recurrence. Between-study heterogeneity and risk of bias were evaluated using graphical and statistical methods. The authors performed a multilevel meta-analysis using random-effects modeling on aggregated data (n = 4447) and individual participant data (n = 1363) with subgroup results summarized as pooled effects. A mixed-effects meta-regression using individual participant data was performed to analyze independently associated variables. RESULTS: The 114 selected articles included data for 5810 patients with 6092 tumors analyzed to determine the expression of three HRs in human meningiomas: PRs, ARs, and ERs. The proportions of HR+ meningiomas were estimated to be 0.76 (95% CI 0.72-0.80) for PR+ and 0.50 (95% CI 0.33-0.66) for AR+ meningiomas. ER+ meningioma detection varied depending on the measurement method used and was 0.06 (95% CI 0.03-0.10) with IHC and 0.11 (95% CI 0.06-0.20) with LB assays. There were associations between age and PR and ER expression that varied between male and female patients. PR+ and AR+ were more common in female patients (OR 1.84, 95% CI 1.47-2.29 for PR and OR 4.16, 95% CI 1.62-10.68 for AR). Additionally, PR+ meningiomas were enriched in skull base locations (OR 1.89, 95% CI 1.03-3.48) and meningothelial histology (OR 1.86, 95% CI 1.23-2.81). A meta-regression showed that PR+ was independently associated with age (OR 1.11 95% CI 1.09-1.13; p < 0.0001) and WHO grade I tumors (OR 8.09, 95% CI 3.55-18.44; p < 0.0001). ER+ was negatively associated with meningothelial histology (OR 0.94, 95% CI 0.86-0.98; p = 0.044) and positively associated with convexity location (OR 1.12, 95% CI 1.05-1.18; p = 0.0003). CONCLUSIONS: The association between HRs and meningioma features has been investigated but unexplained for decades. In this study the authors demonstrated that HR status has a strong association with known meningioma features, including WHO grade, age, female sex, histology, and anatomical location. Identifying these independent associations allows for a better understanding of meningioma heterogeneity and provides a foundation for revisiting targeted hormonal therapy in meningioma on the basis of proper patient stratification according to HR status.
引用
- Miyagishima DF, Sundaresan V, Gutierrez AG, et al. A systematic review and individual participant data meta-analysis of gonadal steroid hormone receptors in meningioma. J Neurosurg. 2023. PMID: 37243565. doi:10.3171/2023.3.JNS221838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。